170 related articles for article (PubMed ID: 38074508)
21. The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS-9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis.
Trauner M; Gulamhusein A; Hameed B; Caldwell S; Shiffman ML; Landis C; Eksteen B; Agarwal K; Muir A; Rushbrook S; Lu X; Xu J; Chuang JC; Billin AN; Li G; Chung C; Subramanian GM; Myers RP; Bowlus CL; Kowdley KV
Hepatology; 2019 Sep; 70(3):788-801. PubMed ID: 30661255
[TBL] [Abstract][Full Text] [Related]
22. Cholesterol dependent downregulation of mouse and human apical sodium dependent bile acid transporter (ASBT) gene expression: molecular mechanism and physiological consequences.
Thomas C; Landrier JF; Gaillard D; Grober J; Monnot MC; Athias A; Besnard P
Gut; 2006 Sep; 55(9):1321-31. PubMed ID: 16484503
[TBL] [Abstract][Full Text] [Related]
23. Obeticholic acid may increase the risk of gallstone formation in susceptible patients.
Al-Dury S; Wahlström A; Panzitt K; Thorell A; Ståhlman M; Trauner M; Fickert P; Bäckhed F; Fändriks L; Wagner M; Marschall HU
J Hepatol; 2019 Nov; 71(5):986-991. PubMed ID: 31254596
[TBL] [Abstract][Full Text] [Related]
24. Ileal Bile Acid Transporter Inhibition for the Treatment of Chronic Constipation, Cholestatic Pruritus, and NASH.
Al-Dury S; Marschall HU
Front Pharmacol; 2018; 9():931. PubMed ID: 30186169
[TBL] [Abstract][Full Text] [Related]
25. Liver-directed gene therapy results in long-term correction of progressive familial intrahepatic cholestasis type 3 in mice.
Aronson SJ; Bakker RS; Shi X; Duijst S; Ten Bloemendaal L; de Waart DR; Verheij J; Ronzitti G; Oude Elferink RP; Beuers U; Paulusma CC; Bosma PJ
J Hepatol; 2019 Jul; 71(1):153-162. PubMed ID: 30935993
[TBL] [Abstract][Full Text] [Related]
26. FXR agonist obeticholic acid induces liver growth but exacerbates biliary injury in rats with obstructive cholestasis.
van Golen RF; Olthof PB; Lionarons DA; Reiniers MJ; Alles LK; Uz Z; de Haan L; Ergin B; de Waart DR; Maas A; Verheij J; Jansen PL; Damink SWO; Schaap FG; van Gulik TM; Heger M
Sci Rep; 2018 Nov; 8(1):16529. PubMed ID: 30409980
[TBL] [Abstract][Full Text] [Related]
27. Mouse organic solute transporter alpha deficiency alters FGF15 expression and bile acid metabolism.
Lan T; Rao A; Haywood J; Kock ND; Dawson PA
J Hepatol; 2012 Aug; 57(2):359-65. PubMed ID: 22542490
[TBL] [Abstract][Full Text] [Related]
28. Metabolic preconditioning protects BSEP/ABCB11
Fuchs CD; Paumgartner G; Wahlström A; Schwabl P; Reiberger T; Leditznig N; Stojakovic T; Rohr-Udilova N; Chiba P; Marschall HU; Trauner M
J Hepatol; 2017 Jan; 66(1):95-101. PubMed ID: 27593105
[TBL] [Abstract][Full Text] [Related]
29. FXR-Dependent Modulation of the Human Small Intestinal Microbiome by the Bile Acid Derivative Obeticholic Acid.
Friedman ES; Li Y; Shen TD; Jiang J; Chau L; Adorini L; Babakhani F; Edwards J; Shapiro D; Zhao C; Carr RM; Bittinger K; Li H; Wu GD
Gastroenterology; 2018 Dec; 155(6):1741-1752.e5. PubMed ID: 30144429
[TBL] [Abstract][Full Text] [Related]
30. A novel ASBT inhibitor, IMB17-15, repressed nonalcoholic fatty liver disease development in high-fat diet-fed Syrian golden hamsters.
Ge MX; Niu WX; Ren JF; Cai SY; Yu DK; Liu HT; Zhang N; Zhang YX; Wang YC; Shao RG; Wang JX; He HW
Acta Pharmacol Sin; 2019 Jul; 40(7):895-907. PubMed ID: 30573812
[TBL] [Abstract][Full Text] [Related]
31. Farnesoid X Receptor Agonist Treatment Alters Bile Acid Metabolism but Exacerbates Liver Damage in a Piglet Model of Short-Bowel Syndrome.
Pereira-Fantini PM; Lapthorne S; Gahan CGM; Joyce SA; Charles J; Fuller PJ; Bines JE
Cell Mol Gastroenterol Hepatol; 2017 Jul; 4(1):65-74. PubMed ID: 28560290
[TBL] [Abstract][Full Text] [Related]
32. Potential therapeutic action of tauroursodeoxycholic acid against cholestatic liver injury via hepatic Fxr/Nrf2 and CHOP-DR5-caspase-8 pathway.
Song G; Weng F; Zou B; Zhao J; Jin J; Yan D; Huang K; Sun X; Liu C; Hu Y; Li Y; Qiu F
Clin Sci (Lond); 2023 Apr; 137(7):561-577. PubMed ID: 36795945
[TBL] [Abstract][Full Text] [Related]
33. Suppression of bile acid synthesis as a tipping point in the disease course of primary sclerosing cholangitis.
Braadland PR; Schneider KM; Bergquist A; Molinaro A; Lövgren-Sandblom A; Henricsson M; Karlsen TH; Vesterhus M; Trautwein C; Hov JR; Marschall HU
JHEP Rep; 2022 Nov; 4(11):100561. PubMed ID: 36176935
[TBL] [Abstract][Full Text] [Related]
34. High expression of the bile salt-homeostatic hormone fibroblast growth factor 19 in the liver of patients with extrahepatic cholestasis.
Schaap FG; van der Gaag NA; Gouma DJ; Jansen PL
Hepatology; 2009 Apr; 49(4):1228-35. PubMed ID: 19185005
[TBL] [Abstract][Full Text] [Related]
35. Nuclear factor-E2-related factor 2 is a major determinant of bile acid homeostasis in the liver and intestine.
Weerachayaphorn J; Mennone A; Soroka CJ; Harry K; Hagey LR; Kensler TW; Boyer JL
Am J Physiol Gastrointest Liver Physiol; 2012 May; 302(9):G925-36. PubMed ID: 22345550
[TBL] [Abstract][Full Text] [Related]
36. Targeting FXR in Cholestasis.
Keitel V; Dröge C; Häussinger D
Handb Exp Pharmacol; 2019; 256():299-324. PubMed ID: 31201556
[TBL] [Abstract][Full Text] [Related]
37. Na
Slijepcevic D; Roscam Abbing RLP; Fuchs CD; Haazen LCM; Beuers U; Trauner M; Oude Elferink RPJ; van de Graaf SFJ
Hepatology; 2018 Sep; 68(3):1057-1069. PubMed ID: 29572910
[TBL] [Abstract][Full Text] [Related]
38. Safety and Sustained Efficacy of the Farnesoid X Receptor (FXR) Agonist Cilofexor Over a 96-Week Open-label Extension in Patients With PSC.
Trauner M; Bowlus CL; Gulamhusein A; Hameed B; Caldwell SH; Shiffman ML; Landis C; Muir AJ; Billin A; Xu J; Liu X; Lu X; Chung C; Myers RP; Kowdley KV
Clin Gastroenterol Hepatol; 2023 Jun; 21(6):1552-1560.e2. PubMed ID: 35934287
[TBL] [Abstract][Full Text] [Related]
39. Baicalein alleviates intrahepatic cholestasis by regulating bile acid metabolism via an FXR-dependent manner.
Huang W; Qian Y; Lin J; Wang F; Kong X; Tan W
Biochem Biophys Res Commun; 2024 Apr; 705():149670. PubMed ID: 38442444
[TBL] [Abstract][Full Text] [Related]
40. The Farnesoid X Receptor: Good for BAD.
Keely SJ; Walters JR
Cell Mol Gastroenterol Hepatol; 2016 Nov; 2(6):725-732. PubMed ID: 28174746
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
